Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
STATUS OF THE CLAIMS: Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, 42, and 44 are pending in this application. Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, and 44 are allowed. Claim 42 is maintained for the reasons of record as set forth today and in the Office Action posted on June 22, 2026.
Response to Arguments & Amendment Regarding
Claim Rejections - 35 USC §§ 112, 1st & 2nd paragraphs
Applicant’s arguments filed September 22, 2026, with respect to Claim Rejections under 35 USC §§ 112, 1st paragraph (i.e., lack of enablement) and 2nd paragraph have been fully considered and are persuasive. Thus, the rejections has been withdrawn.
However, Applicant's arguments filed with respect to Claim 42 rejection under 35 USC §§ 112, 1st paragraph (i.e., lack of enablement) have been fully considered but they are not persuasive as discussed below.
Response to Arguments Regarding
Claim 42 Rejection under 35 USC § 112, first paragraph
Applicant's arguments filed September 22, 2026, have been fully considered but they are not persuasive. Applicant contends that since claim 42 was amended to include “wherein the protein kinase is AXL, KDR, Mer or Met” and that since the disclosure provided by the specification in which assays for determining kinase activity and compound inhibition were disclosed in Tabe 2 of the specification as filed, then the claim is enabled, and thus, complies with 35 USC § 112, first paragraph enablement requirement. However, Applicant arguments are inexact and misplaced.
First, Examiner will remind applicant that there are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is “undue”. These factors include but are not limited to the breadth of the claims; nature of the invention; state of the prior art; level of one of ordinary skill; level of predictability in the art; amount of direction provided by the inventor; existence of working examples; and the quantity of experimentation needed to make or use the invention based on the content of the disclosure.
Claim 42 is directed to a method of treating disorders associated in modulating in vivo activity of protein kinase, wherein the protein kinase is AXL, KDR, Mer or Met.
In light of this, it can be asserted that in spite of the vast expenditure of human and capital resources in recent years, there are no agents that treat all disorders, diseases or syndromes associated in modulating in vivo activity of protein kinase, wherein the protein kinase is AXL, KDR, Mer or Met. In re Hokum, 226 USPQ 353
The breadth of the instant claim 42 is seen to encompass a method for treating disorders associated in modulating in vivo activity of protein kinase, wherein the protein kinase is AXL, KDR, Mer or Met by administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formulae (Ia), (Ib) and (Ic). Applicant fail to specify a particular disorder or disease. Thus, the claim is extremely broad.
The nature of the invention is the treatment of disorders associated in modulating in vivo activity of protein kinase, wherein the through the use of the compounds of Formulae (Ia), (Ib) and (Ic) thereof. Currently, there are no agents that treat these diseases all inclusively.
The treatment of these disorders is highly unpredictable. It is well established that “the scope of enablement varies inversely with the degree of unpredictability of the factors involved,” and physiological activity is generally considered to be an unpredictable factor. See In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).
The applicant has not demonstrated sufficient guidance provided in the form of administration profiles, combination ratios of the active agents or reference to the same in the prior art to provide a skilled artisan with sufficient guidance to practice the instant treatment of disorders claimed. Further, the applicant discloses that an effective amount of the compound will be administered without providing any direction other than that the compounds of the invention have a high therapeutic index and follows this with a definition readily found in a basic pharmacology textbook. It should be noted that the therapeutic index of a drug in humans is almost never known and is only determined through clinical experience.
There is not seen in the disclosure, sufficient evidence to support Applicant’s claims for treating these disorders with all of the compounds of Formulae (Ia), (Ib) and (Ic). A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 27 USPQ2d 1510 (CAFC). The disclosure does not demonstrate sufficient evidence to support the applicant's claim to the treatment. There are not sufficient working examples or data from references of the prior art to provide a nexus between those examples and a method of treating the disorders with the claimed compound.
The level of skill is that of one with a doctoral understanding of these disorder therapeutics. Applicant’s data is not convincing as to make the production and use of pharmaceutical compositions comprising the recited compounds feasible without undue and unpredictable experimentation.
A great deal of experimentation is required for the method of treating disorders associated in modulating in vivo activity of protein kinase wherein the protein kinase is AXL, KDR, Mer or Met. Furthermore, direction, in the form of examples, must be shown to determine what an effective dose may be. The references submitted do not demonstrate this. Therefore, one of ordinary skill in the art would require a significant amount of experimentation in order to determine the effective dosage to treat the multitudes of different types of diseases with the claimed compound individually or in combination with other therapeutic agents.
Thus, it can be safely concluded that the instant case fails to provide an enabling disclosure for the treatment of disorders associated in modulating in vivo activity of protein kinase, wherein the protein kinase is AXL, KDR, Mer or Met.
Allowable Subject Matter
Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, and 44 are allowed. The compounds and process in claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, and 44 were not found to be obvious or anticipated by the prior art of record. The prior art does not teach or suggest the compounds and process substituted in the manner claimed by the Applicant. Therefore, these claims are allowed.
Conclusion
Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, 42, and 44 are pending in this application. Claims 1, 4, 17, 19, 23, 26-29, 35, 37, 40, and 44 are allowed. Claim 42 is rejected
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PAUL V WARD/ Primary Examiner, Art Unit 1622